RXRX logo

RXRX
Recursion Pharmaceuticals Inc

14,611
Mkt Cap
$1.72B
Volume
26.88M
52W High
$7.18
52W Low
$2.98
PE Ratio
-2.19
RXRX Fundamentals
Price
$3.25
Prev Close
$3.37
Open
$3.35
50D MA
$3.92
Beta
2.67
Avg. Volume
22.68M
EPS (Annual)
-$1.44
P/B
1.52
Rev/Employee
$124,468.33
$1,160.13
Loading...
Loading...
News
all
press releases
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.37, indicating a +1.51% shift from the previous trading day.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CFO Ben Taylor sold 7,956 shares of the firm's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the completion of the...
MarketBeat·3d ago
News Placeholder
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells 28,298 Shares of Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CEO Najat Khan sold 28,298 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of...
MarketBeat·10d ago
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CEO Najat Khan sold 28,298 shares of the stock in a transaction dated Monday, March 9th. The stock was sold at an average price of...
MarketBeat·10d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Recursion Pharmaceuticals (RXRX) reached $3.44 at the closing of the latest trading day, reflecting a -1.99% change compared to its last close.
Zacks·11d ago
News Placeholder
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX
ARK Investment Management LLC raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1.7% in the third quarter, according to its most recent disclosure with the SEC...
MarketBeat·17d ago
News Placeholder
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the company, Marketbeat.com...
MarketBeat·20d ago
News Placeholder
Vanguard Group Inc. Purchases 3,708,975 Shares of Recursion Pharmaceuticals, Inc. $RXRX
Vanguard Group Inc. grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 10.3% during the 3rd quarter, according to its most recent Form 13F filing with the...
MarketBeat·20d ago
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Recursion Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·22d ago
News Placeholder
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
Zacks·23d ago
<
1
2
...
>

Latest RXRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.